Iranian Journal of Immunology

Evaluation of SARS-CoV-2 Specific Antibodies in Recovered Patients by Different ELISA Kits

Document Type : Short Communication

Authors

Alireza Fereidouni 1
Hamidreza Safari 2
Hadis Rezapoor 1
Sara Mahmoudzadeh 1
Mohammad Fereidouni 3

1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.

2 Department of Immunology, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran.

3 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

https://doi.org/10.22034/iji.2023.93206.2202
Abstract
Background: The coronavirus disease 2019 (COVID-19) was first reported in December 2019 in Wuhan, Hubei Province of China. As long as the 27th of December 2021, approximately 280 million people have been infected with coronavirus, resulting in more than 5,418,421 deaths worldwide. Since the beginning of the COVID-19 pandemic, different methods were introduced for diagnosing coronavirus-infected patients and evaluating the immune response, following the vaccination.
Objective: The current study aimed to compare the level of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) specific IgG in a group of patients who recovered from COVID-19, measured by three different enzyme-linked immunosorbent assay (ELISA) kits.
Methods: This cross-sectional study was conducted on sera from patients who recovered from a real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 in Birjand, South Khorasan, Iran. SARS-CoV-2 anti-nucleocapsid (N) and spike (S) protein IgG levels were measured using commercial ELISA kits. Comparison between groups was made using one-way ANOVA and Tukey post hoc tests.
Results: The mean titer of anti-N IgG was significantly higher for the PishtazTeb Diagnostics kit than the Ideal Tashkhis Atieh kit (p<0.05). There was no correlation between the titer of anti-N IgG (PishtazTeb Diagnostics and Ideal Tashkhis Atieh) and anti-S IgG (Chemobind Company) antibodies.
Conclusion: This study indicates that the domestic ELISA kits have variable but acceptable sensitivity for detecting SARS-CoV-2 specific IgG antibodies.

Keywords

COVID-19
ELISA Kit
SARS-CoV-2
Serologic Assays
  1. Li X, Zai J, Wang X, Li YJJomv. Potential of large “first generation” human‐to‐human transmission of 2019‐nCoV. 2020;92(4):448-54.
  2. Sohrabi C, Alsafi Z, O'neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). 2020;76:71-6.
  3. Worldometers Covid-19 coronavirus pandemic.
  4. Al-Qahtani M, AlAli S, AbdulRahman A, Alsayyad AS, Otoom S, Atkin SLJIJoID. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. 2021;102:285-8.
  5. Subramanian R, He Q, Pascual MJPotNAoS. Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity. 2021;118(9).
  6. Hernández‐Huerta MT, Mayoral LPC, Navarro LMS, Mayoral‐Andrade G, Mayoral EPC, Zenteno E, et al. Should RT‐PCR be considered a gold standard in the diagnosis of COVID‐19? 2021.
  7. Falaschi Z, Danna PS, Arioli R, Pasché A, Zagaria D, Percivale I, et al. Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: A retrospective correlation with RT-PCR testing and analysis of discordant cases. 2020;130:109192.
  8. Ghaffari A, Meurant R, Ardakani AJD. COVID-19 serological tests: how well do they actually perform? 2020;10(7):453.
  9. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. International journal of biological sciences. 2020;16(10):1718-23.
  10. Valdez-Cruz NA, García-Hernández E, Espitia C, Cobos-Marín L, Altamirano C, Bando-Campos CG, et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial Cell Factories. 2021;20(1):88.
  11. Cohen AN, Kessel BJM. False positives in reverse transcription PCR testing for SARS-CoV-2. 2020.
  12. Li T, Wang L, Wang H, Li X, Zhang S, Xu Y, et al. Serum SARS-COV-2 nucleocapsid protein: a sensitivity and specificity early diagnostic marker for SARS-COV-2 infection. 2020;10.
  13. Coste AT, Jaton K, Papadimitriou-Olivgeris M, Greub G, Croxatto AJJoCV. Comparison of SARS-CoV-2 serological tests with different antigen targets. 2021;134:104690.
  14. Chatterjee SJE, Membrane, SARS-CoV-2 NPo. Understanding the nature of variations in structural sequences coding for coronavirus spike, envelope, membrane and nucleocapsid proteins of SARS-CoV-2. 2020.
  15. Sigrist CJ, Bridge A, Le Mercier PJAr. A potential role for integrins in host cell entry by SARS-CoV-2. 2020;177:104759.
  16. Malik YAJTMjop. Properties of coronavirus and SARS-CoV-2. 2020;42(1):3-11.
  17. Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020;5(1):237.
  18. Shah P, Canziani GA, Carter EP, Chaiken I. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Frontiers in immunology. 2021;12:637651-.
  19. Huang Y, Yang C, Xu X-f, Xu W, Liu S-w. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica. 2020;41(9):1141-9.
  20. Kovac M, Risch L, Thiel S, Weber M, Grossmann K, Wohlwend N, et al. EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA). Diagnostics. 2020;10(8):593.
  21. Coste AT, Jaton K, Papadimitriou-Olivgeris M, Greub G, Croxatto A. Comparison of SARS-CoV-2 serological tests with different antigen targets. J Clin Virol. 2021;134:104690-.
  22. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. 2020;56(2).
  23. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. 2021;59(4):e02438-20.
  24. Zhou F, Li J, Lu M, Ma L, Pan Y, Liu X, et al. Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff: a cross-sectional survey. 2020;26:100510.
  25. Malfertheiner SF, Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, et al. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study. 2020;130:104575.
  26. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. 2020;12(8):6536.
  27. Kubina R, Dziedzic AJD. Molecular and serological tests for COVID-19. A comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. 2020;10(6):434.
  28. Woloshin S, Patel N, Kesselheim ASJNEJoM. False negative tests for SARS-CoV-2 infection—challenges and implications. 2020;383(6):e38.
  29. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. Journal of molecular biology. 2020;432(10):3309-25.
  30. Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS–CoV-2: a target for vaccine development. Journal of virology. 2020;94(13):e00647-20.
  31. Ravindran R, McReynolds C, Yang J, Hammock BD, Ikram A, Ali A, et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PloS one. 2021;16(7):e0254367.
  32. Rockstroh A, Wolf J, Fertey J, Kalbitz S, Schroth S, Lübbert C, et al. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerging Microbes & Infections. 2021;10(1):774-81.
  33. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. The Journal of infectious diseases. 2021;223(3):389-98.
  34. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-42.
  35. Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV). Journal of medical virology. 2020;92(9):1542-8.
  36. Dörschug A, Schwanbeck J, Hahn A, Hillebrecht A, Blaschke S, Mese K, et al. Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies. Diagnostics (Basel, Switzerland). 2021;11(1).
Iranian Journal of Immunology
Volume 20, Issue 3
Summer 2023
Pages 374-381

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us